IN8bio
INAB | NASDAQ
$0.77
-$0.05 (-6.10%)
At close: Nov 16, 2026, 3:59 PM ET
$0.80
+$0.03 (+3.86%)
After-hours:
Nov 16, 2026, 7:52 PM ET
IN8bio Company Profile
Company profile explainedCompany Profile
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Tai-Wei | Co-Founder, CEO & Director |
| Patrick McCall | Chief Financial Officer & Secretary |
| Kate Rochlin | President & COO |
| Lawrence S. Lamb | Executive Vice President, Co-Founder & Chief Scientific Officer |
| Oxana Polyakova | Senior Vice President of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | S-8 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jun 01, 2026 | 8-K | Current Report |
| Jun 01, 2026 | 424B5 | Filing |
| May 29, 2026 | SC 13D/A | [Amend] Filing |
| May 29, 2026 | 4 | Filing |
| May 19, 2026 | EFFECT | Filing |
| May 18, 2026 | S-3/A | [Amend] Filing |
IN8bio
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | William T. |
Contact Details
350 5th Avenue New York City,
New York 10118 United States
Stock Details
| Ticker Symbol | INAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001740279 |
| CUSIP Number | 45674E208 |
| ISIN Number | US45674E2081 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove INAB